BioSpace News Archive

The Honourable Marie-Claude Bibeau, Minister of Agriculture and Agri-Food, will announce measures taken by the Government of Canada to help prevent the introduction of African swine fever into Canada.

Anixa Biosciences, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for an additional cancer detection technology patent.

Alkahest, Inc. will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration in treatment-naïve patients at the Retina World Congress in Fort Lauderdale, Florida on March 24, 2019 at 11:33 a.m. EST.

ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be attending the 31st Annual ROTH Conference to be held on March 17 -19 at the Ritz Carlton Laguna Niguel in Dana Point, California.

BMS Clinical Collaboration on MARIO-275, a Randomized Study of IPI-549 and Opdivo® (nivolumab) in I/O Naïve Urothelial Cancer to be Initiated in 2Q19

KalVista Pharmaceuticals, Inc. provided an operational update and released financial results for the fiscal third quarter ended January 31, 2019.

Don’t call it a comeback. Call it 2.0. Le-Vel, the world leader in human nutritional innovation, just launched THRIVE DFT Ultra 2.0, the next breakthrough in Derma Fusion Technology.

Endo International plc (NASDAQ: ENDP) today announced a series of debt refinancing transactions that are intended to help manage the debt maturity profile of it and certain of its subsidiaries (collectively, the “Company” or “Endo”). These refinancing transactions are expected to include:

Nxt-ID, Inc. (NASDAQ: NXTD) (the “Company”), a provider of healthcare devices and services as well as payment credential management and authentication platform services, announces selected unaudited, preliminary results for year ended December 31, 2018.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife”) today announced that it has entered into an agreement to acquire Astero Bio Corporation (“Astero”), a privately-held innovator in the design, development and commercialization of novel automated thawing devices, for an upfront cash payment of $8.0 million.